The World Health Organization still expects to issue guidance on the naming of biologic drugs, but is keeping its “biological qualifier” proposal on ice until it has assessed the impact of the different approaches being taken by regulators in countries such as the US, Canada and Australia, says François-Xavier Lery, coordinator for technologies, standards and norms at the WHO.
The organization announced last year that it was suspending its proposal for a “biological qualifier” (BQ), which would have consisted...






